德展健康(000813.SZ):轉讓所持中融信託相關信託合同的信託受益權
格隆匯11月25日丨德展健康(000813.SZ)公佈,公司於2021年11月24日召開第八屆董事會第三次會議,審議通過了《關於轉讓中融國際信託受益權的議案》,同意公司與華創國信集團有限公司(“華創國信”)簽署《信託受益權轉讓協議》,將公司持有的中融國際信託有限公司(“中融信託”)《中融-鑫瑞1號結構化集合資金信託計劃之優先級資金信託合同》項下的4億份信託單位(對應信託本金為4億元人民幣)所對應之信託受益權轉讓給華創國信。截止公吿日,公司已收到華創國信支付的第一筆轉讓價款1.491億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.